Advertisement

Cytokines in Allogeneic Stem Cell Mobilization

  • Ravi Vij
  • Randy Brown
  • John F. DiPersio
Part of the Current Clinical Oncology book series (CCO)

Abstract

Since the mid-1990s when the first trials of cytokine-mobilized allogeneic peripheral blood stem cell (allo-PBSC) transplants appeared in the literature, there has been a steady increase in the use of allo-PBSC in lieu of bone marrow as a source of stem cells. For normal donors, the collection of PBSC by apheresis techniques is a feasible alternative to undergoing marrow harvest with anesthesia and avoids the potential morbidity associated with marrow collection. This trend has further accelerated with the publication of a randomized trial suggesting a superior survival for patients where peripheral blood was used as a source of stem cells over the use of bone marrow (1).

Keywords

Stem Cell Acute Myeloid Leukemia Hematopoietic Progenitor Normal Donor Hematopoietic Progenitor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175.PubMedCrossRefGoogle Scholar
  2. 2.
    Liu F, Poursine-Laurent J, Link DC. Expression of the G-CSF receptor on hematopoietic progenitor cells is not required for their mobilization by G-CSF. Blood 2000; 95: 3025–3031.PubMedGoogle Scholar
  3. 3.
    Papayannopoulou T, Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with antiVLA4 integrin. Proc Natl Acad Sci USA 1993; 90: 9374–9378.PubMedCrossRefGoogle Scholar
  4. 4.
    Papayannopoulou T, Craddock C, Nakamoto B, Priestley GV, Wolf NS. The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci USA 1995; 92: 9647–9651.PubMedCrossRefGoogle Scholar
  5. 5.
    Papayannopoulou T, Priestley GV, Nakamoto B. Anti-VLA4/VCAM-1-induced mobilization requires cooperative signaling through the kit/mkit ligand pathway. Blood 1998; 91: 2231–2239.PubMedGoogle Scholar
  6. 6.
    Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001; 98: 1289–1297.PubMedCrossRefGoogle Scholar
  7. 7.
    Laterveer L, Lindley IJ, Hamilton MS, Willemze R, Fibbe WE. Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. Blood 1995; 85: 2269 2275.Google Scholar
  8. 8.
    Laterveer L, Lindley IS, Heemskerk DP, Camps JA, Pauwels EK, Willemze R, Fibbe WE. Rapid mobilization of hematopoietic progenitor cells in rhesus monkeys by a single intravenous injection of interleukin-8. Blood 1996; 87: 781–788.PubMedGoogle Scholar
  9. 9.
    Pruijt JF, van Kooyk Y, Figdor CG, Lindley IJ, Willemze R, Fibbe WE. Anti-LFA-1 blocking antibodies prevent mobilization of hematopoietic progenitor cells induced by interleukin-8. Blood 1998; 91: 4099–4105.PubMedGoogle Scholar
  10. 10.
    Liu F, Poursine-Laurent J, Link DC. The granulocyte colony-stimulating factor receptor is required for the mobilization of murine hematopoietic progenitors into peripheral blood by cyclophosphamide or interleukin8 but not flt-3 ligand. Blood 1997; 90: 2522 2528.Google Scholar
  11. 11.
    Pruijt JF, Fibbe WE, Laterveer L, et al.Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP9). Proc Natl Acad Sci USA 1999;96:10, 863–10, 868.Google Scholar
  12. 12.
    Sweeney EA, Priestley GV, Nakamoto B, Collins RG, Beaudet AL, Papayannopoulou T. Mobilization of stem/ progenitor cells by sulfated polysaccharides does not require selectin presence. Proc Natl Acad Sci USA 2000; 97: 6544–6549.PubMedCrossRefGoogle Scholar
  13. 13.
    Sweeney EA, Papayannopoulou T. Increase in circulating SDF- i after treatment with sulfated glycans. The role of SDF-1 in mobilization. Ann N Y Acad Sci 2001; 938: 48–52.PubMedCrossRefGoogle Scholar
  14. 14.
    Brown RA, Adkins D, Goodnough LT, et al. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies. J Clin Oncol 1997; 15: 3067–3074.PubMedGoogle Scholar
  15. 15.
    Korbling M, Huh YO, Durett A, et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-ldim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842–2848.PubMedGoogle Scholar
  16. 16.
    Moore MA. Expansion of myeloid stem cells in culture. Semin Hematol 1995; 32: 183.PubMedGoogle Scholar
  17. 17.
    Pettengell R, Luft T, Henschler R, et al. Direct comparison by limiting dilution analysis of long-term culture-initiating cells in human bone marrow, umbilical cord blood, and blood stem cells. Blood 1994; 84: 3653–3659.PubMedGoogle Scholar
  18. 18.
    Hoglund M, Smedmyr B, Simonsson B, Totterman T, Bengtsson M. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. Bone Marrow Transplant 1996; 18: 1927.Google Scholar
  19. 19.
    Waller CF, Bertz H, Wenger MK, et al. Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimen. Bone Marrow Transplant 1996; 18: 279283.Google Scholar
  20. 20.
    Lee V, Li CK, Shing MM, et al. Single vs twice daily G-CSF dose for peripheral blood stem cells harvest in normal donors and children with non-malignant diseases. Bone Marrow Transplant 2000; 25: 931–935.PubMedCrossRefGoogle Scholar
  21. 21.
    Anderlini P, Donato M, Lauppe MJ, et al. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. Br J Haematol 2000; 109: 770–772.PubMedCrossRefGoogle Scholar
  22. 22.
    Tjonnfjord GE, Steen R, Evensen SA, Thorsby E, Egeland T. Characterization of CD34+ peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1994; 84: 2795–2801.PubMedGoogle Scholar
  23. 23.
    Grigg AP, Roberts AW, Raunow H, et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437–4445.PubMedGoogle Scholar
  24. 24.
    Dreger P, Haferlach T, Eckstein V, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. BrJHaematol 1994; 87: 609–613.Google Scholar
  25. 25.
    Malachowski ME, Comenzo RL, Hillyer CD, Tiegerman KO, Berkman EM. Large-volume leukapheresis for peripheral blood stem cell collection in patients with hematologic malignancies. Transfusion 1992; 32: 732–735.PubMedCrossRefGoogle Scholar
  26. 26.
    Comenzo RL, Malachowski ME, Miller KB, et al. Engraftment with peripheral blood stem cells collected by large-volume leukapheresis for patients with lymphoma. Transfusion 1992; 32: 729–731.PubMedCrossRefGoogle Scholar
  27. 27.
    Passos-Coelho JL, Braine HG, Wright SK, et al. Large-volume leukapheresis using regional citrate anticoagulation to collect peripheral blood progenitor cells. J Hematother 1995; 4: 11–19.PubMedCrossRefGoogle Scholar
  28. 28.
    Anderlini P, Przepiorka D, Huh Y, et al. Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation. Br J Haematol 1996; 93: 940–942.PubMedCrossRefGoogle Scholar
  29. 29.
    Anderlini P, Przepiorka D, Seong C, et al. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 1997; 37: 507–512.PubMedCrossRefGoogle Scholar
  30. 30.
    Lane TA, Law P, Maruyama M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85: 275–282.PubMedGoogle Scholar
  31. 31.
    Vij R, Brown RA, Adkins D, et al. Mobilization of normal donors with G-CSF + GM-CSF is associated with improved yield of hematopoietic progenitors and increased numbers of activated dendritic cells (abstr). Blood 1998; 92: 682a.Google Scholar
  32. 32.
    Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 90: 4705–4709.Google Scholar
  33. 33.
    Pan L, Delmonte J, Jr., Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422–4429.PubMedGoogle Scholar
  34. 34.
    Fowler DH, Kurasawa K, Smith R, et al. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graftversus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994; 84: 3540–3549.PubMedGoogle Scholar
  35. 35.
    Shenoy S, Mohanakumar T, Todd G, et al. Immune reconstitution following allogeneic peripheral blood stem cell transplants. Bone Marrow Transplant 1999; 23: 335–346.PubMedCrossRefGoogle Scholar
  36. 36.
    Arpinati M, Green CL, Heimfeld S, et al. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484–2490.PubMedGoogle Scholar
  37. 37.
    Miller JS, Prosper F, McCullar V. Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections. Blood 1997; 90: 3098–3105.PubMedGoogle Scholar
  38. 38.
    Ageitos AG, Varney ML, Bierman PJ, et al. Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products. Bone Marrow Transplant 1999; 23: 63–69.PubMedCrossRefGoogle Scholar
  39. 39.
    Joshi SS, Lynch JC, Pavletic SZ, et al. Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics. Blood 2001; 98: 1963–1970.PubMedCrossRefGoogle Scholar
  40. 40.
    Brown RA AD, Haug J, Pence H, et al. Mobilization of allogeneic peripheral blood stem cell donors with both G and GM-CSF increases progenitor yield without impacting graft-vs-host disease (GVHD), relapse risk or progression free survival (PFS)(abstr). Blood 2000; 96: 181a.Google Scholar
  41. 41.
    Anderlini P, Przepiorka D, Korbling M, et al. Blood stem cell procurement: donor safety issues. Bone Marrow Transplant 1998; 21 (Suppl 3): S35 - S39.PubMedGoogle Scholar
  42. 42.
    Parkkali T, Volin L, Siren MK, et al. Acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor. Bone Marrow Transplant 1996; 17: 433, 434.Google Scholar
  43. 43.
    Anderlini P, Przepiorka D, Champlin R, et al. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood 1996; 88: 2819 2825.Google Scholar
  44. 44.
    Anderlini P, Przepiorka D, Seong D, et al. Clinical toxicity and laboratory effects of granulocyte-colonystimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 1996; 36: 590–595.PubMedCrossRefGoogle Scholar
  45. 45.
    Hillyer CD, Tiegerman KO, Berkman EM. Increase in circulating colony-forming units-granulocyte-macrophage during large-volume leukapheresis: evaluation of a new cell separator. Transfusion 1991; 31: 327–332.PubMedCrossRefGoogle Scholar
  46. 46.
    Anderlini P, Przepiorka D, Seong D, et al. Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. Br J Haematol 1996; 94: 155–158.PubMedCrossRefGoogle Scholar
  47. 47.
    Korbling M, Anderlini P, Durett A, et al. Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-ldim CD38-progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplant 1996; 18: 1073–1079.PubMedGoogle Scholar
  48. 48.
    Martinez C, Urbano-Ispizua A, Rozman C, et al. Effects of G-CSF administration and peripheral blood progenitor cell collection in 20 healthy donors. Ann Hematol 1996; 72: 269 272.Google Scholar
  49. 49.
    Sohngen D, Wienen S, Siebler M, et al. Analysis of rhG-CSF-effects on platelets by in vitro bleeding test and transcranial Doppler ultrasound examination. Bone Marrow Transplant 1998; 22: 1087–1090.PubMedCrossRefGoogle Scholar
  50. 50.
    LeBlanc R, Roy J, Demers C, et al. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant 1999; 23: 991–996.PubMedCrossRefGoogle Scholar
  51. 51.
    Falanga A, Marchetti M, Evangelista V, et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood 1999; 93: 2506–2514.PubMedGoogle Scholar
  52. 52.
    Becker PS, Wagle M, Matous S, et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997; 3: 45–49.PubMedGoogle Scholar
  53. 53.
    Falzetti F, Aversa F, Minelli O, et al. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999; 353: 555.PubMedCrossRefGoogle Scholar
  54. 54.
    Vij R, Adkins DR, Brown RA, et al. Unstable angina in a peripheral blood stem and progenitor cell donor given granulocyte-colony-stimulating factor. Transfusion 1999; 39: 542, 543.Google Scholar
  55. 55.
    Freedman MH, Bonilla MA, Fier C, et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood 2000; 96: 429–436.PubMedGoogle Scholar
  56. 56.
    Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997; 90: 1009–1013.PubMedGoogle Scholar
  57. 57.
    Cavallaro AM, Lilleby K, Majolino I, et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000; 25: 85–89.PubMedCrossRefGoogle Scholar
  58. 58.
    Stroncek DF, Clay ME, Herr G, et al. Blood counts in healthy donors 1 year after the collection of granulocytecolony-stimulating factor-mobilized progenitor cells and the results of a second mobilization and collection. Transfusion 1997; 37: 304–308.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Ravi Vij
  • Randy Brown
  • John F. DiPersio

There are no affiliations available

Personalised recommendations